文献速递遗传性与小管间质肾病

长期lumasiran治疗最终结果:一项原发性高草酸尿症2期开放标签扩展研究

Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

该2期开放标签扩展研究纳入20例完成母研究的1型原发性高草酸尿症(PH1)患者,评估长期lumasiran治疗(最长54个月)的安全性和疗效。结果显示治疗相关不良事件主要为轻度一过性注射部位反应,24小时尿草酸显著持续降低,估算肾小球滤过率保持稳定。

要点

  • 20例PH1患者接受长期lumasiran治疗,中位年龄11.5岁,65%为女性。
  • 21例次治疗相关不良事件中13例次为轻度一过性注射部位反应,第18至51个月未报告注射部位反应。
  • 24小时尿草酸自基线至第54个月平均降低1.5 mmol/24 h/1.73 m²,第42至54个月各访视89%-94%患者≤1.5倍正常值上限。

核心结论

  • 长期lumasiran治疗PH1安全性可接受,可持续且大幅降低尿草酸并保持肾功能。

研究设计与样本

  • 2期开放标签扩展研究(NCT03350451),纳入完成1/2期母研究的PH1患者,年龄6至64岁,24小时尿草酸排泄>0.7 mmol/1.73 m²/天,eGFR>45 ml/min/1.73 m²,且在母研究完成后12个月内入组,共20例。

主要发现

  • 全部20例完成母研究的患者均进入并完成2期开放标签扩展研究,中位年龄11.5岁,65%为女性。
  • 427次给药中共报告21例次治疗相关不良事件,其中13例次为一过性注射部位反应,涉及8/20例患者(40%),所有注射部位反应严重程度均为轻度;第18个月至第51个月(末次给药)未报告注射部位反应;未报告治疗相关严重或重度不良事件。
  • lumasiran治疗使24小时尿草酸自基线至第54个月平均降低1.5 mmol/24 h/1.73 m²;第42至第54个月各访视时,89%-94%的患者24小时尿草酸≤1.5倍正常值上限。
  • 总体估算肾小球滤过率年均变化为-0.4 ml/min/1.73 m²/年;基线eGFR<90 ml/min/1.73 m²的患者eGFR也保持稳定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder of hepatic oxalate overproduction leading to kidney failure and systemic oxalosis. Lumasiran is an RNA interference therapeutic approved for lowering urinary oxalate (UOx) and plasma oxalate (POx) in PH1. This Phase 2 open-label extension (OLE) study evaluated the safety and efficacy of long-term lumasiran treatment (up to 54 months) in patients with PH1 who had completed the Phase 1/2 parent study. METHODS: The Phase 2 OLE (NCT03350451) included patients with PH1 6 to 64 years of age, 24-hour UOx excretion >0.7 mmol/1.73 m2/day, and estimated glomerular filtration rate (eGFR >45 ml/min/1.73 m2) who enrolled within 12 months of parent study completion. Patients initiated subcutaneous lumasiran at parent study dosage. Endpoints included adverse event (AE) incidence (primary) and change over time in efficacy measures, including 24-hour UOx and eGFR. RESULTS: All 20 patients (median age 11.5 years; 65% female) who completed the parent study entered and completed the Phase 2 OLE. Of 21 treatment-related AEs over 427 doses, 13 were transient injection site reactions (ISRs), affecting 8/20 patients (40%); all ISRs were mild in severity. After Month (M) 18 through M51 (last dosing), no ISRs were reported. No treatment-related severe or serious AEs were reported. Lumasiran treatment led to a substantial mean reduction in 24-hour UOx from baseline to M54 of -1.5 mmol/24 h/1.73 m2. At visits M42 through M54, 24-hour UOx was ≤1.5 × ULN in 89%-94% of patients at each visit. The mean annual change in eGFR was -0.4 ml/min/1.73 m2/year overall; eGFR was also stable in those patients with baseline eGFR <90 ml/min/1.73 m2. CONCLUSION: These data represent the longest published follow-up of lumasiran-treated patients with PH1 (ages 6-43 years) to date. Long-term lumasiran treatment for PH1 had acceptable safety and led to sustained and substantial reduction of UOx with preservation of kidney function.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Frishberg Y, Groothoff JW, Hulton SA, et al. Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria. Nephrol Dial Transplant. 2026. PMID: 40982237. doi:10.1093/ndt/gfaf188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。